Could a common drug shrink rare growths in Kids' faces and necks?

NCT ID NCT03243019

Recruiting now Disease control Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug rapamycin can shrink large, hard-to-treat lymphatic malformations in the head and neck area of children. Over 6 months, 28 kids will take oral rapamycin, and doctors will measure changes using MRI scans and quality-of-life surveys. The goal is to see if the drug reduces the size of the growths by at least one-fifth and eases symptoms like pain or trouble breathing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rapamycin
What this could lead to: If successful, this could offer a non-surgical treatment option for children with severe lymphatic malformations, reducing pain and improving breathing and swallowing.
What could go wrong: This is a small, early-phase trial with only 28 participants. Rapamycin may not shrink the malformations enough, and side effects like infections or mouth sores are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHATIC MALFORMATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphatic Abnormalities lymphatic malformation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHATIC MALFORMATION PEDIATRIC

Contacts and locations

Locations

Hu Robert Debre Aphp - Paris
RECRUITING

Paris, France
Hôpital Jeanne de Flandres, CHU
RECRUITING

Lille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.